Pharmacotherapy prescribing pattern and outcome for hospitalized patients with severe and critical COVID-19

DOI record: { "DOI": "10.2478/cipms-2022-0020", "ISSN": [ "2300-6676" ], "URL": "http://dx.doi.org/10.2478/cipms-2022-0020", "abstract": "<jats:title>Abstract</jats:title>\n <jats:p>There are many treatment modalities for COVID-19 – with varied outcome. Therefore, authors designed this study to assess prescribing patterns and the clinical outcome for hospitalized patients with severe and critical COVID-19 so as to determine the most effective approach.</jats:p>\n <jats:p>Authors conducted a retrospective observational study on 346 adult patients with either severe or critical COVID-19, who were admitted to public hospitals in Al-Najaf city, Iraq from June to September 2020. Patients’ information, medications and outcomes were collected from their medical records in the registered office of the hospital.</jats:p>\n <jats:p>A total of 346 patients were enrolled, with a majority of patients being adults above 35 years old and male (70.2%). Most patients (81%) received corticosteroid as dexamethasone, and about 45% of all patients were given convalescent plasma therapy, while a few patients were prescribed antiviral favipiravir (23%) and lopinavir/ritonavir (19%). As supportive care medications, anticoagulant such as enoxaparin was administered to most of the patients (93%) and more than half of all patients received the broad-spectrum antibiotic, meropenem.</jats:p>\n <jats:p>The majority of the patients recovered and were discharged alive (66%), however, the in- hospital mortality rate was 26%. Interestingly, patients treated with enoxaparin alone or in combination with hydroxychloroquine were associated with better outcome.</jats:p>\n <jats:p>The prescribing pattern of COVID-19 specific medications and supportive care is aligned with guideline recommendations and associated with a beneficial therapeutic outcome.</jats:p>", "alternative-id": [ "10.2478/cipms-2022-0020" ], "author": [ { "ORCID": "http://orcid.org/0000-0003-3499-3007", "affiliation": [ { "name": "Department of Clinical Pharmacy, Faculty of Pharmacy , University of Kufa , Najaf , Iraq" } ], "authenticated-orcid": false, "family": "Assad", "given": "Hayder", "sequence": "first" } ], "container-title": "Current Issues in Pharmacy and Medical Sciences", "content-domain": { "crossmark-restriction": false, "domain": [] }, "created": { "date-parts": [ [ 2022, 10, 21 ] ], "date-time": "2022-10-21T13:20:19Z", "timestamp": 1666358419000 }, "deposited": { "date-parts": [ [ 2022, 10, 22 ] ], "date-time": "2022-10-22T03:23:54Z", "timestamp": 1666409034000 }, "indexed": { "date-parts": [ [ 2022, 10, 23 ] ], "date-time": "2022-10-23T05:01:56Z", "timestamp": 1666501316838 }, "is-referenced-by-count": 0, "issue": "0", "issued": { "date-parts": [ [ 2022, 10, 21 ] ] }, "journal-issue": { "issue": "0", "published-online": { "date-parts": [ [ 2022, 10, 21 ] ] } }, "language": "en", "license": [ { "URL": "http://creativecommons.org/licenses/by-nc-nd/3.0", "content-version": "unspecified", "delay-in-days": 0, "start": { "date-parts": [ [ 2022, 10, 21 ] ], "date-time": "2022-10-21T00:00:00Z", "timestamp": 1666310400000 } } ], "link": [ { "URL": "https://www.sciendo.com/pdf/10.2478/cipms-2022-0020", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "374", "original-title": [], "prefix": "10.2478", "published": { "date-parts": [ [ 2022, 10, 21 ] ] }, "published-online": { "date-parts": [ [ 2022, 10, 21 ] ] }, "publisher": "Walter de Gruyter GmbH", "reference": [ { "DOI": "10.1001/jama.2020.1097", "doi-asserted-by": "crossref", "key": "2022102203230152355_j_cipms-2022-0020_ref_001", "unstructured": "1. Phelan AL, Katz R, Gostin LO. The Novel Coronavirus Originating in Wuhan, China: Challenges for Global Health Governance. JAMA. 2020;323(8):709-10.10.1001/jama.2020.109731999307" }, { "DOI": "10.1016/j.tmaid.2020.101739", "doi-asserted-by": "crossref", "key": "2022102203230152355_j_cipms-2022-0020_ref_002", "unstructured": "2. Al-Malkey MK, Al-Sammak MA. Incidence of the COVID-19 in Iraq – Implications for travellers. Travel Med Infect Dis. 2020;38:101739.10.1016/j.tmaid.2020.101739721936332405265" }, { "key": "2022102203230152355_j_cipms-2022-0020_ref_003", "unstructured": "3. WHO; 2021. [https://covid19.who.int/] (access: 04 June 2021)" }, { "DOI": "10.1001/jama.2020.1585", "doi-asserted-by": "crossref", "key": "2022102203230152355_j_cipms-2022-0020_ref_004", "unstructured": "4. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061-9.10.1001/jama.2020.1585704288132031570" }, { "DOI": "10.1001/jama.2020.6775", "doi-asserted-by": "crossref", "key": "2022102203230152355_j_cipms-2022-0020_ref_005", "unstructured": "5. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020;323(20):2052-9.10.1001/jama.2020.6775717762932320003" }, { "DOI": "10.1001/jama.2020.6019", "doi-asserted-by": "crossref", "key": "2022102203230152355_j_cipms-2022-0020_ref_006", "unstructured": "6. Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for Coronavirus Disease 2019 (COVID-19): A review. JAMA. 2020;323(18):1824-36.10.1001/jama.2020.601932282022" }, { "DOI": "10.1183/13993003.00815-2020", "doi-asserted-by": "crossref", "key": "2022102203230152355_j_cipms-2022-0020_ref_007", "unstructured": "7. Bajwah S, Wilcock A, Towers R, Costantini M, Bausewein C, Simon ST, et al. Managing the supportive care needs of those affected by COVID-19. Eur Respir J. 2020;55(4):2000815.10.1183/13993003.00815-2020714426832269090" }, { "DOI": "10.1111/jebm.12414", "doi-asserted-by": "crossref", "key": "2022102203230152355_j_cipms-2022-0020_ref_008", "unstructured": "8. Campos DM de O, Fulco UL, de Oliveira CBS, Oliveira JIN. SARSCoV-2 virus infection: Targets and antiviral pharmacological strategies. J Evid Based Med. 2020;13(4):255-60.10.1111/jebm.12414767531533058394" }, { "DOI": "10.1007/s43440-020-00152-9", "doi-asserted-by": "crossref", "key": "2022102203230152355_j_cipms-2022-0020_ref_009", "unstructured": "9. Sahebnasagh A, Avan R, Saghafi F, Mojtahedzadeh M, Sadremomtaz A, Arasteh O, et al. Pharmacological treatments of COVID-19. Pharmacol Rep. 2020;72:1446-78.10.1007/s43440-020-00152-9743963932816200" }, { "DOI": "10.1056/NEJMoa2021436", "doi-asserted-by": "crossref", "key": "2022102203230152355_j_cipms-2022-0020_ref_010", "unstructured": "10. Chappell L, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, et al. Dexamethasone in hospitalized patients with COVID-19 – preliminary report. N Engl J Med. 2021;384(8):693-704.10.1056/NEJMoa2021436738359532678530" }, { "DOI": "10.1016/j.eclinm.2020.100418", "doi-asserted-by": "crossref", "key": "2022102203230152355_j_cipms-2022-0020_ref_011", "unstructured": "11. Kewan T, Covut F, Al-Jaghbeer MJ, Rose L, Gopalakrishna KV, Akbik B. Tocilizumab for treatment of patients with severe COVID-19: A retrospective cohort study. E Clinical Medicine. 2020;24:100418.10.1016/j.eclinm.2020.100418730550532766537" }, { "key": "2022102203230152355_j_cipms-2022-0020_ref_012", "unstructured": "12. WHO; 2021.[https://www.who.int/] (access: 28 June 2021)" }, { "DOI": "10.1002/jmv.27049", "doi-asserted-by": "crossref", "key": "2022102203230152355_j_cipms-2022-0020_ref_013", "unstructured": "13. Best JH, Kong AM, Kaplan-Lewis E, Brawley OW, Baden R, Zazzali JL, et al. Treatment patterns in US patients hospitalized with COVID-19 and pulmonary involvement. J Med Virol. 2021;93:5367-75.10.1002/jmv.27049" }, { "DOI": "10.1016/j.ejphar.2020.173372", "doi-asserted-by": "crossref", "key": "2022102203230152355_j_cipms-2022-0020_ref_014", "unstructured": "14. Chibber P, Haq SA, Ahmed I, Andrabi NI, Singh G. Advances in the possible treatment of COVID-19: A review. Eur J Pharmacol. 2020;883:173372.10.1016/j.ejphar.2020.173372" }, { "DOI": "10.1007/s40265-020-01424-7", "doi-asserted-by": "crossref", "key": "2022102203230152355_j_cipms-2022-0020_ref_015", "unstructured": "15. Lin KJ, Schneeweiss S, Tesfaye H, D’Andrea E, Liu J, Lii J, et al. Pharmacotherapy for hospitalized patients with COVID-19: Treatment patterns by disease severity. Drugs. 2020;80(18):1961-72.10.1007/s40265-020-01424-7" }, { "key": "2022102203230152355_j_cipms-2022-0020_ref_016", "unstructured": "16. Centers for Disease Control and Prevention. Guidance for COVID-19. [https://www.cdc.gov/coronavirus/2019-ncov/communication/guidance.html] (access: 27 June 0 2021)." }, { "DOI": "10.1001/jamanetworkopen.2021.10775", "doi-asserted-by": "crossref", "key": "2022102203230152355_j_cipms-2022-0020_ref_017", "unstructured": "17. Watanabe JH, Kwon J, Nan B, Abeles SR, Jia S, Mehta SR. Medication use patterns in hospitalized patients with COVID-19 in California During the pandemic. JAMA Netw Open. 2021;4(5):e2110775.10.1001/jamanetworkopen.2021.10775" }, { "DOI": "10.1056/NEJMoa2007764", "doi-asserted-by": "crossref", "key": "2022102203230152355_j_cipms-2022-0020_ref_018", "unstructured": "18. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of COVID-19 – Final Report. N Engl J Med. 2020;383(19):1813-26.10.1056/NEJMoa2007764" }, { "key": "2022102203230152355_j_cipms-2022-0020_ref_019", "unstructured": "19. Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395(10236):1569-78.10.1016/S0140-6736(20)31022-9" }, { "DOI": "10.1101/2020.06.24.20133249", "doi-asserted-by": "crossref", "key": "2022102203230152355_j_cipms-2022-0020_ref_020", "unstructured": "20. Rattanaumpawan P, Jirajariyavej S, Lerdlamyong K, Palavutitotai N, Saiyarin J. Real-world experience with favipiravir for treatment of COVID-19 in Thailand: Results from a multi-center observational study. MedRxiv. 2020. [https://doi.org/10.1101/2020.06.24.20133249]10.1101/2020.06.24.20133249" }, { "DOI": "10.1016/j.ajpath.2020.08.001", "doi-asserted-by": "crossref", "key": "2022102203230152355_j_cipms-2022-0020_ref_021", "unstructured": "21. Salazar E, Christensen PA, Graviss EA, Nguyen DT, Castillo B, Chen J, et al. Treatment of Coronavirus Disease 2019 patients with convalescent plasma reveals a signal of significantly decreased mortality. Am J Pathol. 2020;190(11):2290-303.10.1016/j.ajpath.2020.08.001741790132795424" }, { "DOI": "10.1016/j.ijid.2020.11.198", "doi-asserted-by": "crossref", "key": "2022102203230152355_j_cipms-2022-0020_ref_022", "unstructured": "22. Alsharidah S, Ayed M, Ameen RM, Alhuraish F, Rouheldeen NA, Alshammari FR, et al. COVID-19 convalescent plasma treatment of moderate and severe cases of SARS-CoV-2 infection: A multicenter interventional study. Int J Infect Dis. 2021;103:439-46.10.1016/j.ijid.2020.11.198771777233285283" }, { "DOI": "10.1016/j.ijid.2020.06.099", "doi-asserted-by": "crossref", "key": "2022102203230152355_j_cipms-2022-0020_ref_023", "unstructured": "23. Arshad S, Kilgore P, Chaudhry ZS, Jacobsen G, Wang DD, Huitsing K, et al. Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19. Int J Infect Dis. 2020;97:396-403.10.1016/j.ijid.2020.06.099733057432623082" }, { "DOI": "10.1053/j.gastro.2020.05.053", "doi-asserted-by": "crossref", "key": "2022102203230152355_j_cipms-2022-0020_ref_024", "unstructured": "24. Freedberg DE, Conigliaro J, Wang TC, Tracey KJ, Callahan MV, Abrams JA, et al. Famotidine use is associated with improved clinical outcomes in hospitalized COVID-19 patients: A propensity score matched retrospective cohort study. Gastroenterol. 2020;159(3):1129-31.e3.10.1053/j.gastro.2020.05.053724219132446698" }, { "DOI": "10.18433/jpps31457", "doi-asserted-by": "crossref", "key": "2022102203230152355_j_cipms-2022-0020_ref_025", "unstructured": "25. Padhy BM, Mohanty RR, Das S, Meher BR. Therapeutic potential of ivermectin as add on treatment in COVID 19: A systematic review and meta-analysis. J Pharm Pharm Sci. 2020;23:462-9.10.18433/jpps3145733227231" }, { "DOI": "10.1186/s40248-017-0088-1", "doi-asserted-by": "crossref", "key": "2022102203230152355_j_cipms-2022-0020_ref_026", "unstructured": "26. Zanasi A, Mazzolini M, Kantar A. A reappraisal of the mucoactive activity and clinical efficacy of bromhexine. Multidiscip Respir Med. 2017;12(1):1-14.10.1186/s40248-017-0088-1535981728331610" } ], "reference-count": 26, "references-count": 26, "relation": {}, "resource": { "primary": { "URL": "https://www.sciendo.com/article/10.2478/cipms-2022-0020" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [ "Pharmacology", "Molecular Biology", "General Medicine", "Biochemistry" ], "subtitle": [], "title": "Pharmacotherapy prescribing pattern and outcome for hospitalized patients with severe and critical COVID-19", "type": "journal-article", "volume": "0" }